| Identification | Back Directory | [Name]
Imidazo[1,5-a]pyrazin-8(7H)-one, 6-[4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl]-3-(tetrahydro-2H-pyran-4-yl)- | [CAS]
1430840-90-6 | [Synonyms]
Imidazo[1,5-a]pyrazin-8(7H)-one, 6-[4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl]-3-(tetrahydro-2H-pyran-4-yl)- | [Molecular Formula]
C21H26N6O2 | [MOL File]
1430840-90-6.mol | [Molecular Weight]
394.47 |
| Hazard Information | Back Directory | [Description]
IMR687 is a PDE9 inhibitor that slows or stops the hydrolysis of cGMP. This hydrolysis occurs in the caudate nucleus and cerebellum of the CNS, and thus, IMR687 can be regarded as a highly promising drug against Alzheimer's for improving memory. | [Uses]
(Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia[1]. | [References]
[1] Aydinok Y. Highlights on the Luspatercept Treatment in Thalassemia[J]. Thalassemia Reports, 2023, 13(1): 77-84. |
|
|